Skye Bioscience Inc.(US:SKYE) Prnewswire·2025-12-23 16:06Core Viewpoint - The complaint against Skye Bioscience alleges that the company and its executives misled investors regarding the effectiveness and prospects of nimacimab, leading to significant stock price decline following the release of disappointing clinical trial results [2][3]. Group 1: Allegations and Impact - The complaint claims that nimacimab was less effective than previously communicated, resulting in overstated clinical, regulatory, and commercial prospects [2]. - Following the announcement of the Phase 2a study results, Skye's stock price dropped by $2.85 per share, or 60%, closing at $1.90 per share on October 6, 2025 [3]. Group 2: Legal Proceedings - The lead plaintiff in the class action is the investor with the largest financial interest, who will oversee the litigation on behalf of the class [4]. - Any member of the putative class can apply to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [4]. Group 3: Call for Information - The law firm Faruqi & Faruqi encourages individuals with information regarding Skye's conduct to come forward, including whistleblowers and former employees [5].